Corvus Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Corvus Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2015 to Q2 2024.
  • Corvus Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$4.26M, a 34.5% increase year-over-year.
  • Corvus Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$22.6M, a 42% increase year-over-year.
  • Corvus Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$27M, a 34.6% increase from 2022.
  • Corvus Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$41.3M, a 4.47% increase from 2021.
  • Corvus Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$43.2M, a 621% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$22.6M -$4.26M +$2.24M +34.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$24.9M -$5.7M +$2.17M +27.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-06
Q4 2023 -$27M -$6.65M +$3.16M +32.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-19
Q3 2023 -$30.2M -$6M +$8.83M +59.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$39M -$6.5M +$1.86M +22.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$40.9M -$7.87M +$424K +5.11% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-06
Q4 2022 -$41.3M -$9.82M -$580K -6.28% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-19
Q3 2022 -$40.7M -$14.8M -$4.16M -39% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$36.6M -$8.36M +$3.39M +28.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-07
Q1 2022 -$40M -$8.3M +$3.28M +28.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-07
Q4 2021 -$43.2M -$9.24M -$36.6M -134% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-19
Q3 2021 -$6.66M -$10.7M -$877K -8.95% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$5.78M -$11.8M -$1.14M -10.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$4.64M -$11.6M +$1.36M +10.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$6M $27.3M +$38.4M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$44.4M -$9.8M +$1.21M +11% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-10
Q2 2020 -$45.6M -$10.6M +$2.37M +18.2% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-10
Q1 2020 -$48M -$12.9M -$1.29M -11.1% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-10
Q4 2019 -$46.7M -$11M -$538K -5.12% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 -$46.1M -$11M -$506K -4.82% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-25
Q2 2019 -$45.6M -$13M -$1.35M -11.6% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-25
Q1 2019 -$44.3M -$11.6M +$2.66M +18.6% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-25
Q4 2018 -$46.9M -$10.5M +$1.42M +11.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-09
Q3 2018 -$48.4M -$10.5M +$2.22M +17.4% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-09
Q2 2018 -$50.6M -$11.6M +$3.35M +22.4% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-09
Q1 2018 -$53.9M -$14.3M +$1.74M +10.8% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-09
Q4 2017 -$55.7M -$11.9M -$843K -7.6% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-07
Q3 2017 -$54.8M -$12.7M -$2.42M -23.5% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-07
Q2 2017 -$52.4M -$15M -$6.34M -73.3% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-07
Q1 2017 -$46.1M -$16M -$9.69M -153% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-07
Q4 2016 -$36.4M -$11.1M -$5.05M -83.6% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 -$31.3M -$10.3M -$7.15M -227% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-01
Q2 2016 -$24.2M -$8.65M +$11.6M +57.3% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-01
Q1 2016 -$35.8M -$6.35M -$4.43M -232% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-01
Q4 2015 -$31.3M -$6.04M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-10
Q3 2015 -$3.15M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-10
Q2 2015 -$20.2M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-10
Q1 2015 -$1.91M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.